James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology

BURLINGAME, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- James T. Rosenbaum, MD, Senior Vice President of Research at Corvus Pharmaceuticals (Nasdaq: CRVS), was presented with the Distinguished Service Award by the American College of Rheumatology (ACR) at its annual meeting in Philadelphia on November 12, 2022. Dr. Rosenbaum received the ACR’s second highest honor, for his outstanding contributions to rheumatology and care of patients.  

Founded in 1934, the ACR is a not-for-profit, professional association that serves over 8,500 physicians, health professionals, and scientists worldwide. It is committed to advancing the specialty of rheumatology. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatology professionals are experts in the diagnosis, management, and treatment of more than 100 different types of arthritis and rheumatic diseases.

Dr. Rosenbaum joined Corvus in July 2022 to lead the development of CPI-818, the Company’s ITK inhibitor, for the treatment of immune disorders such as T cell lymphomas, autoimmune and allergic diseases. Under Dr. Rosenbaum’s leadership, Corvus’ research and development team has been working to prioritize and prepare protocols for new CPI-818 clinical studies in immune-mediated diseases, with the announcement of next clinical program anticipated in the near-term. In addition, new data from the Company’s Phase 1/1b trial of CPI-818 for T cell lymphoma will be presented at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place in-person and virtually from December 10-13, 2022.

“It is an honor to receive the Distinguished Service Award from the American College of Rheumatology. I have dedicated much of my career to conducting research and providing care to address rheumatic diseases and look forward to advancing new treatment options for these patients with the team at Corvus. We have an exciting opportunity with CPI-818, which is well positioned as the most advanced program targeting ITK inhibition and has demonstrated the ability to modulate immune function of T cells, positioning it for broad potential in autoimmunity and allergic disease,” said Dr. Rosenbaum. “I am very grateful to my family, colleagues, teachers, patients, nominators, the selection committee and the ACR and Rheumatology Research Foundation (RRF). I also recognize that many others are deserving of this honor. My hope is that I can repay the ACR for all the opportunities, education, collegiality and support that it has provided to me and my collaborators.”